Tokyo-based Astellas Pharma and German biopharma, Pantherna Therapeutics, have unveiled a new technology evaluation agreement for the research of mRNA-based regenerative medicine.
The agreement will leverage Pantherna's state-of-the-art mRNA platform — consisting of unique mRNA molecules for enhancing the efficiency of mRNA actions in the body and lipid nanoparticles for efficiently delivering mRNA — and Astellas' drug discovery capabilities. The end goal is to promote research in the field of regenerative medicine and apply it to new treatments.
Pantherna, headquartered in Hennigsdorf, Germany, has been developing first-in-class therapeutics for vascular diseases and now hopes to leverage the unique aspects of its proprietary therapeutic mRNA technology in other indications with high medical need.
Financial terms of the deal were not disclosed.
Read the press release